LogicBio -26% as FDA puts hold on LB-001

LogicBio Therapeutics (NASDAQ:LOGC) has slid 26.3% postmarket after the company announced the FDA has placed a clinical hold on its LB-001, for the treatment of methylmalonic acidemia.

That hold is pending the resolution of clinical and nonclinical questions, the company says. It expects hte questions will be provided in writing within 30 days.

The company submitted an Investigational New Drug application in January with an eye toward a Phase 1/2 clinical trial.

https://seekingalpha.com/news/3540327-logicbiominus-26-fda-puts-hold-on-lbminus-001